The problem is not choice. It is clarity and authenticity.
Researchers and procurement teams are presented with thousands of reagents that appear distinct, yet in many cases share underlying origin, validation limitations, or performance uncertainty. Evidence is fragmented across datasheets, application notes, and marketing claims, making meaningful comparison difficult.
In some cases, the same underlying antibody is marketed under multiple brands, each presented with different validation narratives. This creates an illusion of choice while obscuring shared limitations and shared failure modes.
The consequences are systemic:
- repeated experiments
- wasted reagents and time
- delayed projects
- irreproducible outcomes
- hidden financial and environmental cost
These costs are rarely visible at the point of purchase.
ABMIUM focuses on evidence, not branding.
ABMIUM is being built as an evidence-first platform for RUO life science reagents. Its purpose is to transform scattered performance data into structured, comparable, decision-grade information.
Rather than amplifying claims, ABMIUM focuses on:
- how a reagent has been validated
- under which conditions it performs reliably
- where evidence is strong, limited, or absent
- how performance compares across applications and manufacturers
This enables decisions that are defensible, transparent, and aligned with reproducible research practice.
How ABMIUM creates value
Evidence is structured:
Validation data is organised into consistent formats that support comparison rather than confusion.
Evidence is contextualised:
Performance claims are interpreted in the context of application, conditions, and known limitations.
Evidence is made decision ready:
Information is translated into clarity that can be used by researchers, core facilities, and procurement teams.
